BACKGROUND: The objective of the current study was to follow up the results of phase 1 testing by evaluating the clinical efficacy of the green tea extract Polyphenon E for patients with early stage chronic lymphocytic leukemia (CLL). METHODS: Previously untreated patients with asymptomatic, Rai stage 0 to II CLL and an absolute lymphocyte count (ALC) ≥ 10 × 10(9) /L were eligible for this phase 2 trial. Polyphenon E with a standardized dose of epigallocatechin gallate (EGCG) (2000 mg per dose) was administered twice daily. RESULTS: A total of 42 patients received Polyphenon E at a dose of 2000 mg twice daily for up to 6 months. Of these patients, 29 (69%) had Rai stage I to II disease. Patients received a median of 6 cycles of treatment (range, 1 cycle-6 cycles). The most common grade 3 side effects (according to National Cancer Institute Common Terminology Criteria for Adverse Events) were transaminitis (1 patient), abdominal pain (1 patient), and fatigue (1 patient). Clinical activity was observed, with 13 patients (31%) experiencing a sustained reduction of ≥ 20% in the ALC and 20 of 29 patients (69%) with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all lymph node areas. EGCG plasma levels after 1 month of therapy were found to be correlated with reductions in lymphadenopathy (correlation co-efficient, 0.44; P = .02). Overall, 29 patients (69%) fulfilled the criteria for a biologic response with either a sustained decline ≥ 20% in the ALC and/or a reduction ≥ 30% in the sum of the products of all lymph node areas at some point during the 6 months of active treatment. CONCLUSIONS: Daily oral EGCG in the Polyphenon E preparation was well tolerated by patients with CLL in this phase 2 trial. Durable declines in the ALC and/or lymphadenopathy were observed in the majority of patients.
BACKGROUND: The objective of the current study was to follow up the results of phase 1 testing by evaluating the clinical efficacy of the green tea extract Polyphenon E for patients with early stage chronic lymphocytic leukemia (CLL). METHODS: Previously untreated patients with asymptomatic, Rai stage 0 to II CLL and an absolute lymphocyte count (ALC) ≥ 10 × 10(9) /L were eligible for this phase 2 trial. Polyphenon E with a standardized dose of epigallocatechin gallate (EGCG) (2000 mg per dose) was administered twice daily. RESULTS: A total of 42 patients received Polyphenon E at a dose of 2000 mg twice daily for up to 6 months. Of these patients, 29 (69%) had Rai stage I to II disease. Patients received a median of 6 cycles of treatment (range, 1 cycle-6 cycles). The most common grade 3 side effects (according to National Cancer Institute Common Terminology Criteria for Adverse Events) were transaminitis (1 patient), abdominal pain (1 patient), and fatigue (1 patient). Clinical activity was observed, with 13 patients (31%) experiencing a sustained reduction of ≥ 20% in the ALC and 20 of 29 patients (69%) with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all lymph node areas. EGCG plasma levels after 1 month of therapy were found to be correlated with reductions in lymphadenopathy (correlation co-efficient, 0.44; P = .02). Overall, 29 patients (69%) fulfilled the criteria for a biologic response with either a sustained decline ≥ 20% in the ALC and/or a reduction ≥ 30% in the sum of the products of all lymph node areas at some point during the 6 months of active treatment. CONCLUSIONS: Daily oral EGCG in the Polyphenon E preparation was well tolerated by patients with CLL in this phase 2 trial. Durable declines in the ALC and/or lymphadenopathy were observed in the majority of patients.
Authors: G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade Journal: N Engl J Med Date: 1998-05-21 Impact factor: 91.245
Authors: Kristin R Landis-Piwowar; Congde Huo; Di Chen; Vesna Milacic; Guoqing Shi; Tak Hang Chan; Q Ping Dou Journal: Cancer Res Date: 2007-05-01 Impact factor: 12.701
Authors: Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay Journal: Br J Haematol Date: 2008-03 Impact factor: 6.998
Authors: Cara L Frankenfeld; James R Cerhan; Wendy Cozen; Scott Davis; Maryjean Schenk; Lindsay M Morton; Patricia Hartge; Mary H Ward Journal: Am J Clin Nutr Date: 2008-05 Impact factor: 7.045
Authors: Andrew K Joe; Felice Schnoll-Sussman; Robert S Bresalier; Julian A Abrams; Hanina Hibshoosh; Ken Cheung; Richard A Friedman; Chung S Yang; Ginger L Milne; Diane D Liu; J Jack Lee; Kazeem Abdul; Michelle Bigg; Jessica Foreman; Tao Su; Xiaomei Wang; Aqeel Ahmed; Alfred I Neugut; Esther Akpa; Scott M Lippman; Marjorie Perloff; Powel H Brown; Charles J Lightdale Journal: Cancer Prev Res (Phila) Date: 2015-10-15
Authors: Jesus Lovera; Alexander Ramos; Deidre Devier; Virginia Garrison; Blake Kovner; Tara Reza; Dennis Koop; William Rooney; Anne Foundas; Dennis Bourdette Journal: J Neurol Sci Date: 2015-08-07 Impact factor: 3.181